Covance: New offering applies Chiltern-developed engagement models

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Image Source)
(Image: Getty/Image Source)
LabCorp’s Covance has launched a new dedicated offering for biotech, medical device, and diagnostic companies following its purchase of Chiltern in 2017.

These client segments have specific needs for their clinical trials, which can be different from those of larger biopharma companies​,” said Lewis Cameron, head of Global Clinical Development, Covance.

The offering applies “customized engagement models successfully developed by Chiltern​,” he told us.

Chiltern joined Covance, the drug development division of LabCorp, after being acquired in September 2017​ for $1.2bn.

The new dedicated offering, announced Monday, also provides access to additional resources provided by Covance and LabCorp, said Cameron, and includes access to the Covance MarketPlace, the company’s proprietary model for connecting biotech companies with co-development or investment partners.

Cameron explained the addition of Chiltern strengthened Covance’s “focus on the biotech client segment and deepened our therapeutic expertise, particularly in oncology​.”

“Chiltern also brought comprehensive capabilities in medical device development​,” he said, explaining that the company is “pleased​” with the progress of the Chiltern integration to date.

This offering demonstrates how we’re working to translate the powerful combination of Covance and Chiltern to benefit our clients​.”

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers